Meeting News CoverageVideo

Researcher Shannon Humphrey, MD, discusses ATX-101

SAN FRANCISCO – In this video, Shannon Humphrey, MD, a dermatologist and clinical assistant professor at the University of British Columbia, discusses the potential of ATX-101, a deoxycholic acid injection, for treating submental fat.

Humphrey, who served as an investigator in the phase 3 trial of the product, told Healio.com/Dermatology at the American Academy of Dermatology Annual Meeting that ATX-101 (Kythera Biopharmaceuticals) has the potential to be a niche, non-invasive treatment for submental fat.

“At present, patients who have a significant amount of submental fullness are really limited to surgical options, and this is less desirable for many patients today,” she said.

An FDA advisory committee recently voted to support the approval of ATX-101 as a treatment for submental fat.

SAN FRANCISCO – In this video, Shannon Humphrey, MD, a dermatologist and clinical assistant professor at the University of British Columbia, discusses the potential of ATX-101, a deoxycholic acid injection, for treating submental fat.

Humphrey, who served as an investigator in the phase 3 trial of the product, told Healio.com/Dermatology at the American Academy of Dermatology Annual Meeting that ATX-101 (Kythera Biopharmaceuticals) has the potential to be a niche, non-invasive treatment for submental fat.

“At present, patients who have a significant amount of submental fullness are really limited to surgical options, and this is less desirable for many patients today,” she said.

An FDA advisory committee recently voted to support the approval of ATX-101 as a treatment for submental fat.

    See more from American Academy of Dermatology